ArticleBMC ophthalmology2026
Clinical real-world data evaluation: comparison of central macular thickness after anti-VEGF treatment in diabetic macular edema patients treated with or without topical anti-glaucoma agents.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are research findings suggesting that antiglaucoma agents may reduce aqueous humor outflow and decrease the elimination of intravitreally administered anti-vascular endothelial growth factor agents, prolonging their effect. The aim of this study was to evaluate central macular thickness (CMT) after repeated injections, using real-world data, to provide insight into how this phenomenon may affect clinical outcomes.
methodsOne hundred forty-seven patients with diabetic macular edema (DME) were included in the study;66 patients received topical therapy due to pre-existing glaucoma, either primary open- angle or pseudoexfoliative glaucoma, and 81 patients without glaucoma. CMT values were evaluated before treatment, 1 month after the first three injections, 1 month after the subsequent four injections, and at the end of the first year.
resultsNo significant differences were detected with respect to HbA1c levels, the presence of SRF, or prior photocoagulation (p = 0.085, p = 0.24, and p = 0.3, respectively). There was no difference between anti-glaucoma agent users and control group in CMT measurements 1 month after the first three injections (p = 0.6, p > 0.05). However, measurements taken 1 month after the subsequent four injections were significantly lower in patients using topical anti-glaucoma agents (p = 0.001, p < 0.05). At the 1-year measurement interval, although the values remained lower, the significant difference had disappeared (p = 0.11, p > 0.05). The presence of hyper reflective dots (HRD) was also greater in this group (p = 0.021, p < 0.05). At the 1-year measurement interval, although the values remained lower, the significant difference had disappeared (p = 0.11, p > 0.05). The presence of HRD and the combined presence of SRF and HRD had a significant effect on the changes in the measurements (F (4.412), p = 0.006, Eta
conclusionAlthough the use of topical anti-glaucoma therapy may have a partial effect on reduction of CMT in DME patients receiving anti-vascular endothelial growth factor (anti-VEGF) treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.